You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mantel Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lenalidomide combined with G-CHOP (LO CHOP)
  • Xiamen, Fujian, China
    Bing Xu
Nov 28, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Patient Perspectives in Mantle Cell Lymphoma Clinical Research

Not yet recruiting
  • Mantle Cell Lymphoma
    • San Francisco, California
      Power Life Sciences
    Sep 15, 2023

    T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

    Not yet recruiting
    • T Cell Lymphoma
    • New Haven, Connecticut
      Yale Smilow Cancer Hospital
    Aug 14, 2023

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

    Recruiting
    • Peripheral T-Cell Lymphoma, Not Otherwise Specified
    • Angioimmunoblastic T-cell Lymphoma
    • Changchun, Jilin, China
      The First Bethune Hospital of Jilin University
    Apr 7, 2023

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

    Not yet recruiting
    • Mantle-cell Lymphoma
    • Polatuzumab, bendamustin und rituximab
    • (no location specified)
    May 11, 2023

    Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

    Not yet recruiting
    • Large B-cell Lymphoma
    • (no location specified)
    Oct 3, 2023

    B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

    Not yet recruiting
    • B-cell Non-Hodgkin's Lymphoma
    • SHR-A1912; R-Chemo
    • (no location specified)
    Oct 23, 2023

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

    Not yet recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • +5 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2023